

Transforming Gynecologic Health

Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. Current products include OvaWatch® and Ova1Plus® which are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year.

Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.

Investment Highlights

- Revenue-generating company with a portfolio of proprietary risk assessment assays targeting ovarian cancer, collectively called OvaSuite
- Experienced management team with proven track record of success
- Broad managed care coverage (Ova1Plus and OvaWatch Medicare reimbursement - \$897)
- Strong IP and technology protection
- Transformative in-development test pipeline including EndoCheck, EndoMDx, and OvaMDx

Our OvaSuite Products



OvaWatch, a lab-developed test performed on an FDA approved platform with a 99% Negative Predictive Value, assists in the initial clinical assessment and ongoing monitoring of ovarian malignancy risk in patients with adnexal masses not planned for surgical intervention.



Ova1Plus is a reflex process of two FDA-cleared blood tests, Ova1®, and Overa®, to assess risk of ovarian malignancy in women with adnexal masses planned for surgery.

Recent Developments

7 May 2024

AWH Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts

2 May 2024

AWH Enhances its Commercial Offering with the Formal Launch of the Longitudinal Monitoring Feature of OvaWatch

9 April 2024

AWH Announces Anthem Blue Cross to Provide Coverage for OvaSuite in California

18 March 2024

AWH Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

Fast Facts

Ticker (Exchange)	AWH (NASDAQ)
Stock Price <small>(as of 3/31/24)</small>	\$3.10
Market Cap <small>(as of 3/31/24)</small>	\$38.3M
Outstanding Shares <small>(as of 3/31/24)</small>	12.3M
52-Week Range	\$2.31-\$6.75
Avg. Daily Volume	45,102
Headquarters	Austin, TX
Fiscal Year End	December 31
Cash* Available <small>(as of 3/31/24)</small>	\$3.7M
Product Revenues	1Q24
In Millions	\$2.2
YoY Growth	-7%

*incl cash, cash equivalents and restricted cash

Equity Coverage Analysts

William Blair Andrew Brackmann, CFA	Alliance Global Partners James Molloy
Cantor Fitzgerald Ross Osborn, CFA	

Executive Officers

Nicole Sandford CEO & Board Member
Dr. Torsten Hombeck Chief Financial Officer
Dr. Sandra Milligan President



**Visit Aspira's investor relations webpage
to view our recent R&D Day Presentation.**

Contact us:

investors@aspirawh.com

Aspira Women's Health, Inc.

Corporate Headquarters

3 Enterprise Drive, #220

Shelton CT, 06484

Phone: (844) 277-4721

www.aspirawh.com